Brazil Anti-vascular Endothelial Growth Factor Therapeutics Market Size & Outlook
Brazil anti-vascular endothelial growth factor therapeutics market, 2018-2030 (US$M)
Related Markets
Brazil anti-vascular endothelial growth factor therapeutics market highlights
- The Brazil anti-vascular endothelial growth factor therapeutics market generated a revenue of USD 157.0 million in 2021 and is expected to reach USD 179.8 million by 2028.
- The Brazil market is expected to grow at a CAGR of 2% from 2022 to 2028.
- In terms of segment, eylea was the largest revenue generating product in 2021.
- Eylea is the most lucrative product segment registering the fastest growth during the forecast period.
Anti-vascular endothelial growth factor therapeutics market data book summary
| Market revenue in 2021 | USD 157.0 million |
| Market revenue in 2028 | USD 179.8 million |
| Growth rate | 2% (CAGR from 2021 to 2028) |
| Largest segment | Eylea |
| Fastest growing segment | Eylea |
| Historical data | 2017 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Eylea, Lucentis |
| Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, Brazil accounted for 1.3% of the global anti-vascular endothelial growth factor therapeutics market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In Latin America, Brazil anti-vascular endothelial growth factor therapeutics market is projected to lead the regional market in terms of revenue in 2028.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 78.0 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-Vascular Endothelial Growth Factor Therapeutics Market Scope
Anti-Vascular Endothelial Growth Factor Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Brazil anti-vascular endothelial growth factor therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.05% in 2024. Horizon Databook has segmented the Brazil anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil’s anti-VEGF therapeutics market is anticipated to witness lucrative growth over the forecast period, owing to factors such as increasing government initiatives and a growing patient pool. An article suggests that the prevalence of AMD was around 15.1% in the population aged above 60 years. In addition, around 30.5% of AMD patients belong to the 80 years or above age group.
Moreover, increase in demand for biosimilar drugs can help increase the customer pool for biosimilar players in the market. The annual costs of treating one patient in Brazil were USD 476.65 and USD 11,469.39 for bevacizumab & ranibizumab, respectively.
Reasons to subscribe to Brazil anti-vascular endothelial growth factor therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Brazil anti-vascular endothelial growth factor therapeutics market databook
-
Our clientele includes a mix of anti-vascular endothelial growth factor therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Brazil anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Brazil anti-vascular endothelial growth factor therapeutics market
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
